Brief: Biogen - Expects Q1 2026 GAAP And Non-GAAP EPS Impact Of $0.19 From Charge - SEC Filing
06/04/2026 11:51
April 6 (Reuters) - Biogen Inc BIIB.O: BIOGEN - EXPECTS Q1 2026 GAAP AND NON-GAAP EPS IMPACT OF $0.19 FROM CHARGE - SEC FILING BIOGEN - EXPECTS Q1 2026 $34 MILLION BOUGHT IN-PROCESS RESEARCH AND DEVELOPMENT, UPFRONT AND MILESTONE EXPENSE - SEC FILING Further company coverage: BIIB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biogen
See all newsHealth Rounds: Old cancer drug may help restore fertility for certain women
U.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
Biogen rises; co scales back drug programs acquired through $5.6 bln Apellis deal
Biogen scales back Apellis programs, trims research roles after $5.6 billion buyout